BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Anders-Mansson-PHI-241209-1046

BioStock: Emission rustar Phase Holographic för internationell satsning (investor pitch)

– Investor pitch – Emissionsaktuella Phase Holographic genomför just nu en fullt ut garanterad företrädesemission om cirka 64 Mkr för att öka sin globala försäljning av produkten HoloMonitor, ett avancerat verktyg för icke-invasiv analys av levande celler. Med en redan färdig produkt som kan positioneras på en globalt växande marknad, siktar man på att öka sin närvaro inom den prekliniska sektorn samtidigt som vägen mot kliniska tillämpningar är utstakad. Vd Anders Månsson besökte BioStocks studie för att berätta mer.
PHI-financial-stockholm-pitch

PHI presents at Financial Stockholm

Watch CEO Anders Månsson present the Company and its future plans at the Financial Stockholm investor meeting on December 11th, 2024.
Anders-Mansson-PHI-241209-1046

BioStock: PHI:s vd kommenterar företrädesemissionen

PHI genomför just nu en fullt ut garanterad företrädesemission om cirka 64 Mkr som avslutas den 20 december. För att berätta mer om hur likviden avses användas, samt om satsningarna för att öka den globala försäljningen, besökte bolagets vd Anders Månsson BioStocks studio.
fill or kill podcast

PHI som gäst i Fill or Kill podcast: Avsnitt 506

Lyssna på Fill or Kill intervjun med PHI vd Anders Månsson. Avsnitt 506 – Äntligen lite nya case.
1234…10

Latest News

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)

The shareholders of Phase Holographic Imaging PHI AB (publ), reg.no. 556542-7811, are hereby invited to attend the annual general meeting on 16 October 2025 at 3 p.m. at the company´s office at Skiffervägen 48 in Lund.
A black and white image showing a closeup of the HoloMonitor

PHI provides an update regarding the development progress of the new generation of HoloMonitor®

Phase Holographic Imaging PHI AB (“PHI” or the “Company”), a leading provider of advanced holographic imaging solutions, is pleased to update the market on the development progress of its next-generation of HoloMonitor®, which is scheduled for launch before the end of 2025. With the forthcoming launch of the new generation of HoloMonitor®, the Company will be moving into more clinically focused applications and a new, larger market segment.
A brownish warehouse.

Phase Holographic Imaging Signs New Distributor for Singapore and Malaysia

Phase Holographic Imaging PHI AB (“PHI” or the “Company”), is proud to announce the appointment of a new distributor, Gaia Bioscience Pte Ltd, for Singapore and Malaysia. This strategic partnership marks a significant step in PHI’s expansion into Southeast Asia, strengthening and accelerating its presence in one of the world’s most dynamic life science markets.
See All News